和誉-B(02256.HK):和誉医药拟回购2亿港元股份

智通财经
Mar 03, 2025

智通财经APP讯,和誉-B(02256)公布,于2025年3月3日,公司董事会已批准公司动用2亿港元于市场上购回公司股份。

董事会认为,目前股份的交易价格并未反映其内在价值,而进一步的购回股份计划将提高股份的价值,从而增加对公司股东的回报。

根据此前的购回股份授权,截至2024年12月31日,公司已累计购回2259.4万股股份(“购回股份”),占比已发行股份总数的3.23%,已购回股份已于2024年全部注销,其中1583.3万股购回股份于7月3日注销,剩余676.1万股购回股份于9月30日注销,合计涉资约6874万港元,每股购回价格约2.72港元至3.41港元。

务实履行此前披露的1亿港元注销回购计划,显示出和誉在回馈股东方面强大的执行力。此次公司宣布进一步回购则体现出管理层对公司未来发展的更大信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10